T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zoom
ZM
|
+$3.3B |
| 2 |
Eli Lilly
LLY
|
+$2.75B |
| 3 |
AstraZeneca
AZN
|
+$1.98B |
| 4 |
Coupang
CPNG
|
+$1.54B |
| 5 |
Fortinet
FTNT
|
+$1.48B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NXP Semiconductors
NXPI
|
+$2.34B |
| 2 |
Morgan Stanley
MS
|
+$2.26B |
| 3 |
Airbnb
ABNB
|
+$2.04B |
| 4 |
Qualcomm
QCOM
|
+$1.95B |
| 5 |
NVIDIA
NVDA
|
+$1.81B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 23.35% |
| 2 | Healthcare | 16.19% |
| 3 | Consumer Discretionary | 15.55% |
| 4 | Financials | 12.84% |
| 5 | Communication Services | 12.27% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1226
Baker Hughes
BKR
$63B
| $24.3M | ﹤0.01% |
1,122,655
-4,291
| -0.4% | -$97.7K |
|
1227
Utah Medical Products
UTMD
$230M
| $24.2M | ﹤0.01% |
279,895
-233
| -0.1% | -$20.5K |
|
|
PVBC
1228
DELISTED
Provident Bancorp
PVBC
| $24.2M | ﹤0.01% |
1,681,191
-4,296
| -0.3% | -$54.9K |
|
1229
Stoke Therapeutics
STOK
$2.02B
| $24.2M | ﹤0.01% |
623,192
-126,434
| -17% | -$7.2M |
|
|
SWTX
1230
DELISTED
SpringWorks Therapeutics
SWTX
| $24.1M | ﹤0.01% |
327,679
+1,499
| +0.5% | +$117K |
|
1231
John B. Sanfilippo & Son
JBSS
$989M
| $24M | ﹤0.01% |
265,340
-22,943
| -8% | -$1.99M |
|
1232
Wabtec
WAB
$49.9B
| $23.9M | ﹤0.01% |
302,534
-899,025
| -75% | -$69.8M |
|
1233
American Airlines Group
AAL
$9.97B
| $23.9M | ﹤0.01% |
999,029
+652
| +0.1% | +$12.6K |
|
1234
Protagonist Therapeutics
PTGX
$9.8B
| $23.7M | ﹤0.01% |
913,590
+68,195
| +8% | +$1.73M |
|
|
ABCM
1235
DELISTED
Abcam PLC
ABCM
| $23.6M | ﹤0.01% |
1,227,632
+27,022
| +2% | +$595K |
|
1236
Eastman Chemical
EMN
$8.29B
| $23.6M | ﹤0.01% |
214,170
-18,150
| -8% | -$1.97M |
|
1237
FMC
FMC
$1.28B
| $23.5M | ﹤0.01% |
212,611
-13,999
| -6% | -$1.55M |
|
1238
STRATTEC Security
STRT
$341M
| $23.5M | ﹤0.01% |
500,632
-1,617
| -0.3% | -$83K |
|
|
MORF
1239
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $23.4M | ﹤0.01% |
+370,507
| New | +$17M |
|
1240
Service Corp International
SCI
$11.5B
| $23.3M | ﹤0.01% |
456,077
-480,728
| -51% | -$24.1M |
|
1241
Solid Biosciences
SLDB
$972M
| $23.3M | ﹤0.01% |
+280,600
| New | +$31M |
|
1242
Columbia Financial
CLBK
$1.21B
| $23.1M | ﹤0.01% |
1,320,765
-95,629
| -7% | -$1.59M |
|
1243
Pultegroup
PHM
$24.6B
| $23M | ﹤0.01% |
437,752
-34,666
| -7% | -$1.62M |
|
1244
Boston Properties
BXP
$10.8B
| $22.8M | ﹤0.01% |
225,496
-16,648
| -7% | -$1.62M |
|
1245
Diageo
DEO
$52.8B
| $22.7M | ﹤0.01% |
138,492
+2,352
| +2% | +$385K |
|
1246
J.M. Smucker
SJM
$12.7B
| $22.7M | ﹤0.01% |
179,592
-20,897
| -10% | -$2.47M |
|
1247
Murphy USA
MUSA
$10.1B
| $22.6M | ﹤0.01% |
156,671
-131,418
| -46% | -$17M |
|
1248
908 Devices
MASS
$414M
| $22.6M | ﹤0.01% |
465,287
-107,713
| -19% | -$6.16M |
|
1249
Whirlpool
WHR
$2.79B
| $22.4M | ﹤0.01% |
101,742
-6,172
| -6% | -$1.23M |
|
|
CCXI
1250
DELISTED
ChemoCentryx, Inc.
CCXI
| $22.4M | ﹤0.01% |
436,276
+33,148
| +8% | +$1.99M |
|
Similar funds
T. Rowe Price Associates's Q1 2021 Portfolio in Review
As of Q1 2021, T. Rowe Price Associates held 2,908 positions worth $999B, up 2.5% from $974B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
T. Rowe Price Associates's Q1 2021 filing shows 248 new, 1,171 increased, 1,334 reduced and 66 closed positions. Its largest new stake was Coupang: 33,380,859 shares worth $1.63B. The largest sale was NXP Semiconductors, an estimated $2.34B.
By sector, the portfolio is most concentrated in Technology at 23% of assets, down from 25% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q1 2021 buy was Coupang: 33,380,859 shares worth $1.63B.
- T. Rowe Price Associates added most to Zoom in Q1 2021, an estimated $3.3B increase.
- T. Rowe Price Associates's biggest Q1 2021 reduction was NXP Semiconductors, cutting an estimated $2.34B.
- T. Rowe Price Associates fully exited CONCHO RESOURCES INC. in Q1 2021, selling an estimated $205M.
- T. Rowe Price Associates's ten largest holdings make up 24% of its $999B portfolio in Q1 2021.
- T. Rowe Price Associates opened 248 new positions and closed 66 in Q1 2021.
- T. Rowe Price Associates's portfolio value rose 2.5% quarter-over-quarter to $999B.
Based on T. Rowe Price Associates's 13F filing for Q1 2021, filed 17 May 2021.